Autophagy: revision 1 to 2 — Future Human Wiki

Revision 1

Revision 2

categories: ["longevity"]

tags: ["aging", "autophagy", "lysosome", "mtor", "cell biology", "mechanisms"]

summary: "The lysosomal pathway by which cells digest their own damaged components, and the process through which most known lifespan-extending interventions appear to act."

summary: "The lysosomal pathway by which cells digest their own damaged components, and the process through which most known lifespan-extending interventions appear to act."

updated: "2026-07-27"

updated: "2026-10-29"

humanEvidence: "The pathway itself is established in human cells, but autophagic flux cannot be measured in a living person, and every lifespan result comes from yeast, worms, flies and mice."

humanEvidence: "The pathway itself is established in human cells, but autophagic flux cannot be measured in a living person, and every lifespan result comes from yeast, worms, flies and mice."

issues: ["The spermidine claims in the human-data paragraph carry no citations."]

---

"caption": "Cellular degradation pathway",

"rows": [

{ "label": "Named", "value": "1963, by Christian de Duve" },

{ "label": "Genetics established", "value": "1992–1993, yeast screens" },

{ "label": "Genetics established", "value": "1992-1993, yeast screens" },

{ "label": "Nobel Prize", "value": "2016, Yoshinori Ohsumi" },

{ "label": "Core genes", "value": "ATG family, ~40 in yeast" },

{ "label": "Main negative regulator", "value": "mTORC1" },

}

```

**Autophagy** is the process by which a cell delivers its own cytoplasmic contents — misfolded proteins, damaged organelles, invading bacteria, surplus lipid — to the lysosome for degradation and recycling. It is the bulk arm of [[proteostasis|protein quality control]] and the only route by which a cell can dispose of a structure too large for the proteasome. Disabled macroautophagy was added as a separate entry to the [[hallmarks-of-aging]] in 2023, and interfering with autophagy genes abolishes the lifespan extension produced by most known geroprotective interventions in invertebrates.

**Autophagy** is the process by which a cell delivers its own cytoplasmic contents (misfolded

proteins, damaged organelles, invading bacteria, surplus lipid) to the lysosome for degradation and

recycling. It is the bulk arm of [[proteostasis|protein quality control]] and the only route by

which a cell can dispose of a structure too large for the proteasome. Disabled macroautophagy was

added as a separate entry to the [[hallmarks-of-aging]] in 2023. In invertebrates, interfering with

autophagy genes abolishes the lifespan extension produced by most known geroprotective

interventions.

```keyfacts

[

## Three forms

Macroautophagy, the form usually meant by the unqualified term, engulfs cargo in a double-membraned vesicle that then fuses with a lysosome. Microautophagy invaginates the lysosomal membrane directly to take up small volumes of cytosol. Chaperone-mediated autophagy is selective for individual proteins carrying a KFERQ-like motif, which HSC70 recognizes and delivers to the lysosomal receptor LAMP2A for unfolding and direct translocation across the membrane. Only mammals and some other vertebrates have the third form; it declines steeply with age in rodent liver.

Macroautophagy, the form usually meant by the unqualified term, engulfs cargo in a double-membraned

vesicle that then fuses with a lysosome. Microautophagy takes up small volumes of cytosol by

invaginating the lysosomal membrane directly. Chaperone-mediated autophagy selects individual

proteins carrying a KFERQ-like motif: HSC70 recognizes the motif and delivers the protein to the

lysosomal receptor LAMP2A, where it is unfolded and translocated directly across the membrane. Only

mammals and some other vertebrates have this third form, and it declines steeply with age in rodent

liver.

## Mechanics

Macroautophagy begins with the ULK1 kinase complex nucleating an isolation membrane, or phagophore, at a site supplied with lipid by ATG9-containing vesicles and by the class III phosphatidylinositol 3-kinase complex built around VPS34 and Beclin-1. Two ubiquitin-like conjugation cascades then act on the growing membrane. The first builds an ATG12–ATG5–ATG16L1 complex; the second, using that complex as its ligase, attaches LC3 to the lipid phosphatidylethanolamine in the phagophore membrane. Lipidated LC3 recruits cargo receptors, drives membrane expansion, and remains the standard experimental marker of autophagosome formation.

Macroautophagy begins when the ULK1 kinase complex nucleates an isolation membrane, or phagophore.

Lipid reaches the site from ATG9-containing vesicles and from the class III phosphatidylinositol

3-kinase complex built around VPS34 and Beclin-1. Two ubiquitin-like conjugation cascades then act

on the growing membrane. The first builds an ATG12-ATG5-ATG16L1 complex; the second uses that

complex as its ligase to attach LC3 to the lipid phosphatidylethanolamine in the phagophore

membrane. Lipidated LC3 recruits cargo receptors and drives membrane expansion, and it remains the

standard experimental marker of autophagosome formation.

The closed autophagosome traffics along microtubules and fuses with a lysosome. Acid hydrolases degrade the contents, and permeases return amino acids, fatty acids and nucleosides to the cytosol. The whole cycle takes minutes.

The closed autophagosome travels along microtubules and fuses with a lysosome. Acid hydrolases

degrade the contents, and permeases return amino acids, fatty acids and nucleosides to the cytosol.

The whole cycle takes minutes.

## Discovery

[

  { "year": "1955", "title": "Lysosome identified", "text": "Christian de Duve characterizes the lysosome by cell fractionation, establishing that cells contain a dedicated degradative compartment." },

  { "year": "1955", "title": "Lysosome identified", "text": "Christian de Duve characterizes the lysosome by cell fractionation, establishing that cells contain a dedicated degradative compartment." },

  { "year": "1963", "title": "Autophagy named", "text": "De Duve coins the term for the observation that lysosomes sometimes contain recognizable pieces of the cell's own cytoplasm." },

  { "year": "1963", "title": "Autophagy named", "text": "De Duve coins the term for the observation that lysosomes sometimes contain recognizable pieces of the cell's own cytoplasm." },

  { "year": "1992–1993", "title": "Genes found", "text": "Yoshinori Ohsumi observes autophagic bodies accumulating in protease-deficient yeast vacuoles and identifies a set of genes required for the process." },

  { "year": "1992-1993", "title": "Genes found", "text": "Yoshinori Ohsumi observes autophagic bodies accumulating in protease-deficient yeast vacuoles and identifies a set of genes required for the process." },

  { "year": "2003–2008", "title": "Link to longevity", "text": "Work in C. elegans shows autophagy genes are required for the lifespan extension produced by reduced insulin/IGF-1 signalling, dietary restriction and TOR inhibition." },

  { "year": "2003-2008", "title": "Link to longevity", "text": "Work in C. elegans shows autophagy genes are required for the lifespan extension produced by reduced insulin/IGF-1 signalling, dietary restriction and TOR inhibition." },

  { "year": "2016", "title": "Nobel Prize", "text": "Ohsumi receives the Nobel Prize in Physiology or Medicine for elucidating the mechanisms of autophagy." }

  { "year": "2016", "title": "Nobel Prize", "text": "Ohsumi receives the Nobel Prize in Physiology or Medicine for elucidating the mechanisms of autophagy." }

]

```

De Duve saw autophagy in electron micrographs and named it, but the process resisted study for three decades because it lacked genetic handles. Ohsumi's contribution was to make it tractable: by blocking vacuolar proteases in yeast so that autophagic bodies accumulated visibly, he created a screenable phenotype and identified the core machinery, which turned out to be conserved from yeast to humans.[^tsukada1993]

De Duve saw autophagy in electron micrographs and named it, but for three decades the process

resisted study because it lacked genetic handles. Ohsumi made it tractable. By blocking vacuolar

proteases in yeast so that autophagic bodies accumulated visibly, he created a screenable phenotype

and identified the core machinery, which turned out to be conserved from yeast to

humans.[^tsukada1993]

## Regulation

Autophagy is controlled by the same nutrient-sensing network that governs growth. mTORC1, active when amino acids and growth factors are abundant, phosphorylates ULK1 and ATG13 and holds initiation off; it also phosphorylates TFEB, the transcription factor that drives lysosomal and autophagy gene expression, keeping it out of the nucleus. AMPK, active when the AMP:ATP ratio rises, does the opposite on both counts. Starvation, exercise and [[rapamycin]] therefore converge on the same switch from different directions, which is why [[caloric-restriction|dietary restriction]] and mTOR inhibition produce overlapping transcriptional signatures.

The nutrient-sensing network that governs growth also controls autophagy. mTORC1, active when amino

acids and growth factors are abundant, phosphorylates ULK1 and ATG13 and holds initiation off. It

also phosphorylates TFEB, the transcription factor that drives lysosomal and autophagy gene

expression, which keeps TFEB out of the nucleus. AMPK, active when the AMP:ATP ratio rises, does the

opposite on both counts. Starvation, exercise and [[rapamycin]] therefore act on the same switch

from different directions, which is why [[caloric-restriction|dietary restriction]] and mTOR

inhibition produce overlapping transcriptional signatures.

## Selective autophagy

Bulk autophagy is non-specific, but most autophagy under normal conditions is selective. Cargo is ubiquitinated and recognized by receptors — p62/SQSTM1, NBR1, optineurin, NDP52 — which bind both the tag and LC3 on the forming membrane. Named subtypes include mitophagy for [[mitochondrial-dysfunction|damaged mitochondria]], aggrephagy for protein aggregates, lipophagy for lipid droplets, ferritinophagy for iron stores, and xenophagy for intracellular pathogens. Mitophagy is the subtype most directly tied to aging, and the PINK1–Parkin route that governs it is mutated in familial early-onset Parkinson's disease.

Bulk autophagy is non-specific, but under normal conditions most autophagy is selective. Cargo is

ubiquitinated and recognized by receptors such as p62/SQSTM1, NBR1, optineurin and NDP52, which bind

both the tag and LC3 on the forming membrane. Named subtypes include mitophagy for

[[mitochondrial-dysfunction|damaged mitochondria]], aggrephagy for protein aggregates, lipophagy for

lipid droplets, ferritinophagy for iron stores, and xenophagy for intracellular pathogens. Mitophagy

is the subtype most directly tied to aging, and the PINK1-Parkin route that governs it is mutated in

familial early-onset Parkinson's disease.

Selectivity matters for a specific reason in aging biology. Adult stem cells depend on autophagy to clear the damaged mitochondria and protein aggregates that would otherwise be partitioned asymmetrically at division, and loss of autophagy in haematopoietic and muscle stem cells produces a prematurely aged, myeloid-biased or poorly regenerating compartment in mice — a direct mechanistic bridge to [[stem-cell-exhaustion|stem cell exhaustion]]. In macrophages, failure to degrade cytosolic DNA and damaged organelles activates inflammasome signalling, one of the proposed sources of [[inflammaging|chronic sterile inflammation]].

Selectivity matters to aging biology for a specific reason. Adult stem cells depend on autophagy to

clear damaged mitochondria and protein aggregates that would otherwise be partitioned asymmetrically

at division. In mice, loss of autophagy in haematopoietic and muscle stem cells produces a

prematurely aged compartment that is myeloid-biased or regenerates poorly, a direct mechanistic link

to [[stem-cell-exhaustion|stem cell exhaustion]]. In macrophages, failure to degrade cytosolic DNA

and damaged organelles activates inflammasome signalling, one of the proposed sources of

[[inflammaging|chronic sterile inflammation]].

## Why longevity interventions route through it

The strongest evidence that autophagy is not incidental to aging comes from epistasis. In *C. elegans*, autophagy genes were shown to be required for the lifespan extension of the long-lived insulin-signalling mutants [[cynthia-kenyon|Cynthia Kenyon's]] laboratory characterized, and later for the extension produced by dietary restriction and by TOR inhibition.[^melendez2003][^hansen2008] The pattern holds in *Drosophila*. Gain-of-function experiments in mice point the same way: animals engineered to express extra ATG5, and animals carrying a Beclin-1 point mutation that frees it from inhibition by BCL2, both show elevated basal autophagy, better metabolic health, and extended lifespan.[^pyo2013][^fernandez2018]

The strongest evidence that autophagy is more than incidental to aging comes from epistasis. In *C.

elegans*, autophagy genes were shown to be required for the lifespan extension of the long-lived

insulin-signalling mutants that [[cynthia-kenyon|Cynthia Kenyon's]] laboratory characterized, and

later for the extension produced by dietary restriction and by TOR

inhibition.[^melendez2003][^hansen2008] The pattern holds in *Drosophila*. Gain-of-function

experiments in mice point the same way. Animals engineered to express extra ATG5, and animals

carrying a Beclin-1 point mutation that frees it from inhibition by BCL2, both show elevated basal

autophagy, better metabolic health and extended lifespan.[^pyo2013][^fernandez2018]

The argument is epistatic rather than sufficient. Showing that autophagy is required for an intervention's effect does not show that raising autophagy alone would reproduce it, and the mouse gain-of-function experiments alter the pathway from conception rather than in an already-aged animal. Drugs promoted on autophagy grounds — [[metformin]] through AMPK, [[nad-precursors|NAD⁺ precursors]] through sirtuin-dependent regulation of the machinery — have not been shown to raise autophagic activity in human tissue at the doses used.

The epistasis experiments show that autophagy is required, not that it is sufficient. Finding that an

intervention's effect depends on autophagy does not show that raising autophagy alone would

reproduce the effect, and the mouse gain-of-function experiments alter the pathway from conception,

not in an already-aged animal. Drugs promoted on autophagy grounds, such as [[metformin]] acting

through AMPK and [[nad-precursors|NAD⁺ precursors]] acting through sirtuin-dependent regulation of

the machinery, have not been shown to raise autophagic activity in human tissue at the doses used.

> [!key] Why this matters

> Autophagy is the mechanism that most candidate longevity interventions have in common. Rapamycin, dietary restriction, exercise, spermidine and several NAD⁺-related manipulations all raise autophagic activity in model systems, which is either evidence that autophagy is the shared final pathway or evidence that autophagy is easy to raise and easy to measure.

> Most candidate longevity interventions share autophagy as a mechanism. Rapamycin, dietary

> restriction, exercise, spermidine and several NAD⁺-related manipulations all raise autophagic

> activity in model systems. That is evidence either that autophagy is the shared final pathway or

> that autophagy is easy to raise and easy to measure.

Human data are much weaker. [[exercise-and-aging|Exercise]] induces autophagy in mouse muscle, and the metabolic benefits of exercise are lost in mice unable to mount that response. Spermidine, a polyamine that induces autophagy across species and is abundant in some fermented foods, extends lifespan in yeast, flies, worms and mice, and is associated with lower mortality in observational human cohorts; randomized trials of [[dietary-supplements|supplementation]] in older adults have not shown clear cognitive benefit. Autophagy is an explicit programme focus for at least one well-funded longevity company, [[retro-biosciences|Retro Biosciences]].

Human data are much weaker. [[exercise-and-aging|Exercise]] induces autophagy in mouse muscle, and

mice unable to mount that response lose the metabolic benefits of exercise. Spermidine, a polyamine

that induces autophagy across species and is abundant in some fermented foods, extends lifespan in

yeast, flies, worms and mice and is associated with lower mortality in observational human cohorts;

randomized trials of [[dietary-supplements|supplementation]] in older adults have not shown clear

cognitive benefit. At least one well-funded longevity company,

[[retro-biosciences|Retro Biosciences]], names autophagy as an explicit programme focus.

## Limits and counterexamples

More autophagy is not uniformly better. Established tumours depend on autophagy to survive nutrient stress, which is why autophagy inhibitors such as hydroxychloroquine have been trialled as cancer adjuvants — the opposite of the geroprotective logic. Monoallelic loss of *BECN1* is found in some breast and ovarian cancers, so the pathway is tumour-suppressive in one phase and tumour-supporting in another, a pattern it shares with [[cellular-senescence|cellular senescence]]. Variants in *ATG16L1* predispose to Crohn's disease through impaired handling of intestinal bacteria rather than through any failure of recycling.

More autophagy is not uniformly better. Established tumours depend on autophagy to survive nutrient

stress, which is why autophagy inhibitors such as hydroxychloroquine have been trialled as cancer

adjuvants, the reverse of the geroprotective logic. Monoallelic loss of *BECN1* is found in some

breast and ovarian cancers, so the pathway suppresses tumours in one phase and supports them in

another, a pattern it shares with [[cellular-senescence|cellular senescence]]. Variants in *ATG16L1*

predispose to Crohn's disease through impaired handling of intestinal bacteria rather than through

any failure of recycling.

There is also a measurement problem that limits every human claim in this article. Autophagy is a flux, not a level. A high LC3-II signal can mean rapid autophagosome formation or blocked degradation, and distinguishing the two requires adding a lysosomal inhibitor, which cannot be done in a living person. No assay of autophagic flux has been qualified as an [[aging-biomarkers|aging biomarker]], and the field's human evidence therefore rests on downstream functional endpoints rather than on the pathway itself. The consequence is that the central claim — that raising autophagy in an aged human would slow the processes described by the [[geroscience-hypothesis|geroscience hypothesis]] — is currently untestable rather than untested.

A measurement problem limits every human claim in this article. Autophagy is a flux, not a level. A

high LC3-II signal can mean rapid autophagosome formation or blocked degradation, and telling the

two apart requires adding a lysosomal inhibitor, which cannot be done in a living person. No assay

of autophagic flux has been qualified as an [[aging-biomarkers|aging biomarker]], so the field's

human evidence rests on downstream functional endpoints instead of on the pathway itself. As a

result, the central claim, that raising autophagy in an aged human would slow the processes

described by the [[geroscience-hypothesis|geroscience hypothesis]], is at present untestable rather

than merely untested.

## See also